KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNTech SE (BNTX) EBT Margin (2018 - 2025)

Historic EBT Margin for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to 1.63%.

  • BioNTech SE's EBT Margin fell 111200.0% to 1.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.23%, marking a year-over-year decrease of 59200.0%. This contributed to the annual value of 24.63% for FY2024, which is 556900.0% down from last year.
  • Latest data reveals that BioNTech SE reported EBT Margin of 1.63% as of Q3 2025, which was down 111200.0% from 154.41% recorded in Q2 2025.
  • BioNTech SE's 5-year EBT Margin high stood at 85.2% for Q4 2021, and its period low was 626.11% during Q2 2024.
  • Over the past 5 years, BioNTech SE's median EBT Margin value was 44.84% (recorded in 2023), while the average stood at 35.14%.
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by -3803100bps in 2024, then skyrocketed by 4717000bps in 2025.
  • Quarter analysis of 5 years shows BioNTech SE's EBT Margin stood at 85.2% in 2021, then dropped by -13bps to 74.16% in 2022, then plummeted by -40bps to 44.84% in 2023, then plummeted by -44bps to 25.31% in 2024, then crashed by -94bps to 1.63% in 2025.
  • Its last three reported values are 1.63% in Q3 2025, 154.41% for Q2 2025, and 243.65% during Q1 2025.